THELISHA GLOVER: Open Payments
NPI 1063094522 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,621 in 37 payments from 12 companies in 2025. Trend: 2023 $468 · 2024 $972 · 2025 $1,621
Food & beverage: $1,621
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $551 |
| Janssen Biotech, Inc. | 6 | $359 |
| Phathom Pharmaceuticals, Inc. | 4 | $224 |
| Madrigal Pharmaceuticals | 1 | $150 |
| GENZYME CORPORATION | 4 | $111 |
| Boston Scientific Corporation | 2 | $53 |
| PFIZER INC. | 2 | $43 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Novo Nordisk Inc | 1 | $21 |
Products named: TREMFYA, VOQUEZNA, RINVOQ, REZDIFFRA, DUPIXENT, LINZESS, VELSIPITY, XIFAXAN.
Industry payments across GA — which companies pay providers there.
